Uterine Cancer
Treatment in Malaysia

Hello, I’m Dr. Christina Ng Van Tze, a Consultant Medical Oncologist and Medical Director at Onco Life Centre, as well as the Founder President of Empowered The Cancer Advocacy Society of Malaysia. Throughout my career, I have been passionate about advancing personalized cancer treatment, strengthening community advocacy, and expanding access to high-quality care for patients across Malaysia.

Attending the ESMO Congress 2025 in Berlin was both inspiring and energizing. Representing Onco Life Centre, our dedicated medical centre in Malaysia, I stood among global leaders committed to shaping the future of oncology. This year’s congress was filled with remarkable scientific breakthroughs, thoughtful discussions, and a renewed sense of purpose as we work toward better outcomes and better lives for our patients.

A Global Gathering Focused on Precision Cancer Care

ESMO 2025 brought together thousands of clinicians, researchers, and advocates from around the world. What made this year particularly exciting was the strong emphasis on precision medicine, from cancer genetics and molecular profiling to advanced imaging and AI-powered diagnostic tools. These advancements are aligning closely with the work we do at Onco Life Centre, where patient individuality and tumor biology guide our treatment decisions.

Throughout the congress, many experts highlighted the importance of understanding each patient’s tumor in greater depth. Whether through genomic sequencing, circulating tumor DNA, or radiomic analyses, the oncology community is moving firmly toward personalized strategies. As someone who has long championed individualized care, I found these sessions especially meaningful.

Key Scientific Sessions That Inspired Me

One of the standout presentations was the evERA BC trial, a major study evaluating the combination of giredestrant, an oral SERD, with an mTOR inhibitor drug in hormone receptor-positive breast cancer. The results showed a significant improvement in progression-free survival, especially in tumors driven by ESR1 mutations. For patients who have progressed on CDK4/6 inhibitors, this combination may become an essential addition to our treatment toolbox.

This study also supports a larger movement within oncology—creating thoughtful, layered treatment plans that address resistance pathways and extend the time patients can remain on endocrine-based therapies. It’s a direction that can profoundly benefit Malaysian women, many of whom are diagnosed at younger ages or have aggressive tumor profiles.

Insights from the thoracic oncology sessions were equally impactful. Advances in lung cancer, including AI-driven pathology models, updated ALK-targeted treatment strategies, and ctDNA-guided therapy adjustments, reminded me just how quickly this field is evolving. Given the increasing prevalence of lung cancer in Malaysia, especially among non-smokers and women, these developments hold tremendous value for our community.

The Role of AI in Transforming Clinical Practice

One major theme across the congress was the integration of artificial intelligence into clinical decision-making. Researchers demonstrated how AI models can analyze pathology slides, radiology images, and genomic data to predict which patients are more likely to respond to immunotherapy or targeted treatment. These tools help us avoid ineffective therapies and guide patients toward options with the most tremendous potential.

At Onco Life Centre, we have been exploring the use of digital technologies to streamline assessments and enhance patient monitoring. Seeing the global oncology community embrace these tools assures me that we are moving in the right direction. I hope that AI will continue to improve early detection, refine treatment selection, and ultimately support better survival outcomes for Malaysian patients.

Representing Onco Life Centre on the International Stage

Representing Onco Life Centre at an event of this scale was a true honor. Our centre has always focused on delivering holistic, science-driven care, and it was wonderful to share our experiences with colleagues from around the world. I had meaningful conversations about challenges related to access to molecular testing globally, variability in treatment availability, and the need for stronger psycho-oncology support systems.

These interactions not only validated the work we do but also highlighted areas where we can continue to grow. Bringing international insights back to Malaysia ensures that our patients benefit from the same cutting-edge thinking shaping care in Europe, America, and beyond.

Bringing ESMO Insights Home to Malaysia

Returning from Berlin, I feel a renewed commitment to integrating the latest research into our daily practice. In the coming months, we aim to:

• Enhance our use of molecular profiling for breast, lung, and gastrointestinal cancers
• Expand ctDNA testing where appropriate to guide treatment decisions
• Strengthen multidisciplinary discussions for complex cases
• Continue investing in supportive care and psycho-oncology services
• Provide patients and families with clearer, more personalized education about treatment choices

As a clinician, I believe that every advancement, no matter how technical, must ultimately translate into compassionate, human-centered care. This balance of science and empathy remains at the core of our mission.

A Future of Hope and Collaboration

ESMO 2025 reaffirmed what I’ve always believed: oncology is advancing rapidly, but meaningful progress relies on collaboration, continuous learning, and a deep commitment to patient care. I’m genuinely grateful for the opportunity to represent Onco Life Centre on this global platform. Being part of these critical conversations strengthens our mission to raise the standard of oncology in Malaysia. It ensures our patients benefit from the latest, most effective innovations in cancer care.

Moving forward, we will continue engaging with global partners, conducting meaningful advocacy through Empowered, and ensuring our patients receive the highest standard of personalized treatment.

Together, we can build a future where every individual facing cancer feels seen, supported, and empowered.